Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2274-2282

  Heng, Siow Chin ^a   Slavin, Monica A ^b   Chen, Sharon C A ^c   Heath, Christopher H ^d   Nguyen, Quoc ^e   Billah, Baki ^a   Nation, Roger L ^a   Kong, David C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Costs; Fungal infection; Haematology; Outcome; Scedosporium

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG COST; FEMALE; HEMATOLOGIC MALIGNANCY; HOSPITAL ADMISSION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MALE; MORTALITY; PSEUDALLESCHERIASIS; RETROSPECTIVE STUDY; SCEDOSPORIUM; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HEMATOLOGIC DISEASES; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; RISK FACTORS; SCEDOSPORIUM; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84865350221     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks210     Document Type: Article

References (33)

1. Cooley L, Spelman D, Thursky K et al. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 2007; 13: 1170-7.
2. Wood GM, McCormack JG, Muir DB et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992; 14: 1027-33.
3. Guarro J, Kantarcioglu AS, Horré R et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 2006; 44: 295-327.
4. Berenguer J, Rodriguez-Tudela JL, Richard C et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore) 1997; 76: 256-65.
5. Husain S, Alexander BD, Muñoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221-9.
6. Husain S, Muñoz P, Forrest G et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
7. Revankar SG, Patterson JE, Sutton DA et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34: 467-76.
8. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007; 67: 1803-12.
9. Lackner M, Rezusta A, Villuendas MC et al. Infection and colonisation due to Scedosporium in northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses 2011; 54 Suppl 3: 12-21.
10. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16: 607-12.
11. Castiglioni B, Sutton DA, Rinaldi MG et al. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 2002; 81: 333-48.
12. Lamaris GA, Chamilos G, Lewis RE et al. Scedosporium infection in a tertiary care cancer center: A review of 25 cases from 1989-2006. Clin Infect Dis 2006; 43: 1580-4.
13. Gil-Lamaignere C, Roilides E, Maloukou A et al. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50: 1027-30.
14. Slavin MA. Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008. Intern Med J 2008; 38: 457-67.
15. Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-50.
16. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
17. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000; 31: 1524-8.
18. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-8.
19. Slavin M, Fastenau J, Sukarom I et al. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis 2004; 8: 111-20.
20. Slobbe L, Polinder S, Doorduijn JK et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemiamyelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008; 47: 1507-12.
21. Tong KB, Lau CJ, Murtagh K et al. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009; 13: 24-36.
22. Graves N, Harbarth S, Beyersmann J et al. Estimating the cost of health care-associated infections: mind your p's and q's. Clin Infect Dis 2010; 50: 1017-21.
23. Heath CH, Slavin MA, Sorrell TC et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 2009; 15: 689-93.
24. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
25. Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 2011; 54: e301-12.
26. Australian Government of Health and Ageing. National Hospital Cost Data Collection. Round 13 (2008-09) Cost Report Version 5.2. http://www.health.gov.au/internet/main/publishing.nsf/Content/EB1A34EB4E8208ECCA25773B00031A09/%File/HeaderR13CWNatEst.pdf (4 December 2011, date last accessed).
27. Australian Government of Health and Ageing. Medicare Benefits Schedule Book (2010). http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/BBE433BF3FE34A39CA257735001236D4/%File/201007-MBS.pdf (1 August 2011, date last accessed).
28. Health Purchasing Victoria. Health Purchasing Victoria Tender (2010-2012). http://www.hpv.org.au (3 November 2010, date last accessed).
29. Australian Bureau of Statistics. Consumer Price Index (2010). http://www.ausstats.abs.gov.au/ausstats/meisubs.nsf/0/1DEAFC5A0E1C2B5CA25798F000D359F/%File/64010_dec%202011.pdf (1 August 2010, date last accessed).
30. Organisation for Economic Co-operation and Development (OECD). Purchasing Power Parity. http://stats.oecd.org/Index.aspx?datasetcode_ SNA_TABLE4 (1 May 2011, date last accessed).
31. Wilson LS, Reyes CM, Stolpman M et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26-34.
32. Menzin J, Meyers JL, Friedman M et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009; 66: 1711-7.
33. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47: 359-70.